CLINICAL TRIALS PROFILE FOR TRIZIVIR
✉ Email this page to a colleague
All Clinical Trials for TRIZIVIR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00004981 ↗ | Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir) | Unknown status | Glaxo Wellcome | Phase 3 | 1969-12-31 | The purpose of this study is to look at the safety and effectiveness of a pill called Trizivir that is a combination of three anti-HIV drugs (zidovudine, lamivudine, and abacavir). Zidovudine and lamivudine are often given combined in one pill (Combivir). In this study, Trizivir will be compared to Combivir plus abacavir. |
| NCT00011895 ↗ | Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs | Unknown status | GlaxoSmithKline | Phase 4 | 2001-02-01 | The purpose of this study is to determine the effect of treatment with Trizivir (TZV) plus efavirenz (EFV) or TZV alone on viral load (level of HIV in the blood). |
| NCT00038506 ↗ | Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure | Completed | ViiV Healthcare | Phase 4 | 2002-03-01 | This study is a 48-week study to evaluate the efficacy and safety of an investigational regimen combining FDA approved HIV drugs in antiretroviral-experienced subjects failing on their first highly active antiretroviral therapy regimen. |
| NCT00043888 ↗ | Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR | Completed | GlaxoSmithKline | Phase 3 | 2002-01-01 | Antiretroviral Therapy (ART) naive subjects will be enrolled in this clinical research study to test the safety and tolerability of fosamprenavir with or without ritonavir in combination TRIZIVIR and COMBIVIR. Subjects will receive 24 weeks of therapy. |
| NCT00082394 ↗ | A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV | Completed | GlaxoSmithKline | Phase 4 | 2004-04-26 | The aim of this study was to assess whether TRIZIVIR, administered twice-daily was as safe, tolerable and efficacious as a combination of the drugs COMBIVIR administered twice-daily and atazanavir administered once daily. Over the course of 48 weeks, various parameters that measure safety, tolerability and efficacy of the investigational drugs were measured and compared. |
| NCT00084149 ↗ | Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | 2004-02-01 | Cyclosporine A (CsA) is a common long-term treatment used to inhibit the immune response in transplant patients who receive donor organs. CsA may also help people with HIV. The purpose of this study is to determine the safety of and immune response to CsA when given with abacavir sulfate (ABC), lamivudine (3TC), and zidovudine (AZT), (ABC/3TC/AZT) and lopinavir/ritonavir (LPV/r) to HIV infected adults in the early stages of infection. Study hypothesis: The combination of CsA and LPV/r given to acutely infected individuals will result in lower levels of proviral DNA and latent infectious virus at 48 weeks compared to acute infected individuals treated with LPV/r alone. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TRIZIVIR
Condition Name
Clinical Trial Locations for TRIZIVIR
Trials by Country
Clinical Trial Progress for TRIZIVIR
Clinical Trial Phase
Clinical Trial Sponsors for TRIZIVIR
Sponsor Name
